Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

Vanguard Group Inc. increased its position in Castle Biosciences, Inc. (NASDAQ:CSTL) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,832,535 shares of the company’s stock after purchasing an additional 83,783 shares during the quarter. Vanguard Group Inc. owned approximately 6.54% of Castle Biosciences worth $48,837,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its position in shares of Castle Biosciences by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after acquiring an additional 40,377 shares in the last quarter. State Street Corp lifted its stake in Castle Biosciences by 9.8% during the third quarter. State Street Corp now owns 680,001 shares of the company’s stock worth $19,394,000 after purchasing an additional 60,924 shares during the period. Geode Capital Management LLC boosted its holdings in Castle Biosciences by 1.1% during the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock valued at $17,820,000 after purchasing an additional 7,004 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Castle Biosciences by 2.8% in the 4th quarter. New York State Common Retirement Fund now owns 189,101 shares of the company’s stock valued at $5,040,000 after purchasing an additional 5,170 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Castle Biosciences by 2.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 168,713 shares of the company’s stock worth $4,496,000 after buying an additional 3,255 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Stock Up 2.1 %

Shares of NASDAQ CSTL opened at $19.70 on Friday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The company has a market cap of $568.13 million, a price-to-earnings ratio of 98.50 and a beta of 1.11. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm’s 50-day simple moving average is $22.34 and its 200 day simple moving average is $27.10.

Wall Street Analyst Weigh In

Several research firms have issued reports on CSTL. Stephens reiterated an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Robert W. Baird increased their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the company a “buy” rating in a research report on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $38.75.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 2,130 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the sale, the insider now owns 78,335 shares in the company, valued at $1,529,099.20. The trade was a 2.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,071 shares of company stock worth $775,682. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.